Post by
Mhae88 on Feb 21, 2021 4:28am
About GRAT
FSD Pharma Inc. is a publicly-traded holding company.
Comment by
Mhae88 on Feb 21, 2021 4:30am
FSD Pharma BioSciences, Inc., a wholly-owned subsidiary, is a specialty biotech pharmaceutical R&D company focused on developing over time multiple applications of its lead compound, FSD201, by down-regulating the cytokines to effectuate an anti-inflammatory response.
Comment by
Mhae88 on Feb 21, 2021 4:30am
The Company filed an IND with the U.S. Food and Drug Administration (“FDA”) on August 28, 2020 and was approved on September 25, 2020 to initiate a phase 2 clinical trial for the use of FSD201 to treat COVID-19, the disease caused by the SARS-CoV-2 virus.
Comment by
Mhae88 on Feb 21, 2021 4:32am
Severe COVID-19 is characterized by an over-exuberant inflammatory response that may lead to a cytokine storm and ultimately death. The Company is focused on developing FSD201 for its anti-inflammatory properties to avoid the cytokine storm associated with acute lung injury in hospitalized COVID-19 patients.